Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMV0KW)

Drug Name
Ephedrine Drug Info
Synonyms
Biophedrin; Eciphin; Efedrin; Ephedral; Ephedremal; Ephedrin; Ephedrital; Ephedrol; Ephedrosan; Ephedrotal; Ephedsol; Ephendronal; Ephoxamin; Fedrin; Kratedyn; Lexofedrin; Manadrin; Mandrin; Nasol; Racephedrine; Sanedrine; Vencipon; Zephrol; CPDD 0049; D-Ephedrine; Ephedrine (TN); Ephedrine (USP); Ephedrine [USAN:BAN]; Ephedrine l-form; I-Sedrin; L-Ephedrine; L(-)-Ephedrine; L-(+)-Ephedrine; L-(-)-Ephedrine; (+)-Ephedrin; (1R,2R)-Ephedrine; (1S,2R)-Ephedrine; (L)-EPHEDRINE; 1-EPHEDRINE; 1-Sedrin
Therapeutic ClassCentral Nervous System Stimulants
Cross-matching ID
PubChem CID
9294
ChEBI ID
CHEMBL15407
CAS Number
CAS 299-42-3
TTD Drug ID
D0LG8E
INTEDE Drug ID
DR0586
ACDINA Drug ID
D00233

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.37 0.00e+0 34/36 (94.44%) PCNA;RFC5;MCM3;...
Ribosome biogenesis in eukaryotes 2.08 0.00e+0 52/108 (48.15%) FBL;NOP56;IMP3;...
Base excision repair 1.87 1.34e-2 29/33 (87.88%) PCNA;PARP2;NTHL1;...
Homologous recombination 1.86 1.61e-2 35/41 (85.37%) BARD1;RAD51C;BRCA1;...
Mucin type O-glycan biosynthesis -1.71 4.11e-2 20/36 (55.56%) GALNT7;GCNT1;B4GALT5;...
Cytokine-cytokine receptor interaction -1.71 4.56e-2 246/295 (83.39%) LTA;AMH;CXCR1;...
Mitophagy -1.76 3.08e-2 56/68 (82.35%) TBC1D15;RRAS;CSNK2A2;...
Arginine and proline metabolism -1.77 3.52e-2 39/50 (78%) CKMT2;ALDH18A1;ALDH3A2;...
Vibrio cholerae infection -1.80 2.54e-2 44/50 (88%) SEC61G;KDELR3;SEC61B;...
Systemic lupus erythematosus -1.81 2.58e-2 45/135 (33.33%) HLA-DRB1;CD40LG;C6;...
Synaptic vesicle cycle -1.82 2.93e-2 63/78 (80.77%) UNC13B;AP2S1;SLC17A6;...
Complement and coagulation cascades -1.83 3.13e-2 76/85 (89.41%) TFPI;CFB;C5;...
Collecting duct acid secretion -1.83 4.69e-2 22/27 (81.48%) ATP6V1G1;ATP6V1F;ATP6V0E2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H, 24H